Vericel Co. (NASDAQ:VCEL) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. decreased its holdings in Vericel Co. (NASDAQ:VCEL) by 17.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,448 shares of the biotechnology company’s stock after selling 1,389 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Vericel were worth $272,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of VCEL. International Assets Investment Management LLC boosted its holdings in Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 619 shares during the period. CWM LLC boosted its stake in shares of Vericel by 319.0% in the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 504 shares during the period. Farther Finance Advisors LLC grew its position in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after buying an additional 322 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in Vericel by 9.7% in the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 220 shares during the last quarter.

Insider Activity at Vericel

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at approximately $443,850. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the transaction, the director now directly owns 11,000 shares in the company, valued at $443,850. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the sale, the chief executive officer now owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,166 shares of company stock worth $1,200,764 in the last three months. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on VCEL shares. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. Stephens increased their price objective on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group initiated coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. TD Cowen boosted their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Canaccord Genuity Group started coverage on shares of Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.71.

Vericel Price Performance

VCEL stock opened at $55.89 on Wednesday. The company has a market cap of $2.76 billion, a price-to-earnings ratio of 946.33 and a beta of 1.66. The company has a fifty day moving average price of $44.37 and a 200 day moving average price of $46.49. Vericel Co. has a 12 month low of $32.31 and a 12 month high of $57.81.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The firm had revenue of $57.91 million for the quarter, compared to analysts’ expectations of $55.32 million. As a group, analysts anticipate that Vericel Co. will post 0.13 earnings per share for the current year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.